Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WANG Xiaodong ¹ , ZENG Yu ^1,2 ,  LI Li ¹

1. Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Medicine, Sichuan University, Chengdu 610041, P. R. China;

Corresponding?author：

LI Li, Email: drlili116@126.com

Keywords：

colorectal cancer; database; big data; adjuvant therapy; tag; structure

DOI：

10.7507/1007-9424.202106113

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explain details of the adjuvant therapy of colorectal cancer in detail as well as their tags and structures of Database from Colorectal Cancer (DACCA) in the West China Hospital.Method The article was described in words.Results The details of the adjuvant therapy of colorectal cancer included adjuvant treatment therapies, the necessity of adjuvant intravenous chemotherapy, the acceptance of adjuvant chemotherapy, the number of courses of adjuvant chemotherapy, the toxicity of adjuvant chemotherapy, the evaluation of curative effect after adjuvant chemotherapy, the standardized degree of adjuvant chemotherapy, targeted therapy, the necessity of adjuvant radiotherapy, the availability of specialty physicians recommending adjuvant radiotherapy to patients with colorectal cancer, the acceptance of adjuvant radiotherapy, radiotherapy related adverse reactions, and effect evaluation after adjuvant radiotherapy of the DACCA in the West China Hospital were defined. The data labels corresponding to each item in the database and the structured ways needed for the big data application stage in detail were explained. And the error correction notes for all classification items were described.Conclusions Through the detailed description of the details of the adjuvant therapy of colorectal cancer of DACCA in West China Hospital, it provides the standard and basis for the clinical application of DACCA in the future, and provides reference for other peers who wish to build a colorectal cancer database.

Citation： WANG Xiaodong, ZENG Yu, LI Li. Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(8): 1070-1077. doi: 10.7507/1007-9424.202106113 Copy

1.	汪曉東, 林容若, 劉健博, 等. 數據庫建設第七部分: 結直腸癌手術特征的標簽與結構化(二). 中國普外基礎與臨床雜志, 2020, 27(10): 1295-1300.
2.	汪曉東, 林容若, 劉健博, 等. 數據庫建設第七部分: 結直腸癌手術特征的標簽與結構化(一). 中國普外基礎與臨床雜志, 2020, 27(9): 1150-1152.
3.	CSCO 臨床數據委員會. CSCO database. https://www.sinyoo.net/csco/. 2015.
4.	博識醫療云公司數據庫. https://www.boshicloud.com/. 2014.
5.	明智醫療公司數據庫. http://www.wiseltd.cn/. 2015.
6.	中華人民共和國國家衛生健康委員會. 中國結直腸癌診療規范(2020 年版). 中華外科雜志, 2020, 58(8): 561-585.
7.	Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer, 2018, 9(22): 4092-4098.
8.	Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol, 2018, 29(3): 624-631.
9.	劉勇, 汪曉東, 朱佳怡, 等. 數據庫研究第十部分: 結直腸癌的輔助治療特征分析. 中國普外基礎與臨床雜志, 2021, 28(7): 937-944.
10.	Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase Ⅱa trial. J Nutr, 2019, 149(7): 1133-1139.
11.	Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22(2): 229-237.
12.	Hwang J, Marshall JL. Targeted therapy for colorectal cancer. Curr Opin Investig Drugs, 2006, 7(12): 1062-1066.
13.	Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.

1. 汪曉東, 林容若, 劉健博, 等. 數據庫建設第七部分: 結直腸癌手術特征的標簽與結構化(二). 中國普外基礎與臨床雜志, 2020, 27(10): 1295-1300.
2. 汪曉東, 林容若, 劉健博, 等. 數據庫建設第七部分: 結直腸癌手術特征的標簽與結構化(一). 中國普外基礎與臨床雜志, 2020, 27(9): 1150-1152.
3. CSCO 臨床數據委員會. CSCO database. https://www.sinyoo.net/csco/. 2015.
4. 博識醫療云公司數據庫. https://www.boshicloud.com/. 2014.
5. 明智醫療公司數據庫. http://www.wiseltd.cn/. 2015.
6. 中華人民共和國國家衛生健康委員會. 中國結直腸癌診療規范(2020 年版). 中華外科雜志, 2020, 58(8): 561-585.
7. Iwamoto S, Maeda H, Hazama S, et al. Efficacy of CapeOX plus cetuximab treatment as a first-line therapy for patients with extended RAS/BRAF/PIK3CA wild-type advanced or metastatic colorectal cancer. J Cancer, 2018, 9(22): 4092-4098.
8. Yamada Y, Denda T, Gamoh M, et al. S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase Ⅲ, noninferiority trial. Ann Oncol, 2018, 29(3): 624-631.
9. 劉勇, 汪曉東, 朱佳怡, 等. 數據庫研究第十部分: 結直腸癌的輔助治療特征分析. 中國普外基礎與臨床雜志, 2021, 28(7): 937-944.
10. Howells LM, Iwuji COO, Irving GRB, et al. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase Ⅱa trial. J Nutr, 2019, 149(7): 1133-1139.
11. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol, 2004, 22(2): 229-237.
12. Hwang J, Marshall JL. Targeted therapy for colorectal cancer. Curr Opin Investig Drugs, 2006, 7(12): 1062-1066.
13. Engstrom PF, Arnoletti JP, Benson AB, et al. NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw, 2009, 7(8): 838-881.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Part Ⅹ of database building: tag and structure of the adjuvant therapy of colorectal cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content